Activated natural killer cell therapy

ImmunityBio reports significant progress with ANKTIVA's approval and permanent J-code assignment for treating BCG-unresponsive bladder cancer CIS, marking a major advancement in treatment options.

ImmunityBio's Anktiva, combined with BCG, seeks approval in the EU and UK for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).

Hoag Family Cancer Institute is participating in the LIBERATE study, which uses Focused Ultrasound to temporarily open the blood-brain barrier for liquid biopsies in glioblastoma patients.

The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J9028) for ANKTIVA, effective January 1, 2025, to streamline billing.

Recent advancements in DLL3-targeted therapies, including antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapies, are offering new hope for patients with small-cell lung cancer (SCLC). Despite challenges, these therapies have demonstrated potential in improving clinical outcomes, with ongoing clinical trials exploring their efficacy and safety.